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Background: Generic atypical antipsychotic drugs offer health authorities opportunities for considerable savings.
However, schizophrenia and bipolar disorders are complex diseases that require tailored treatments. Consequently,
generally there have been limited demand-side measures by health authorities to encourage the preferential
prescribing of generics. This is unlike the situation with hypertension, hypercholaesterolaemia or acid-related
stomach disorders.
The objectives of this study were to compare the effect of the limited demand-side measures in Western European
countries and regions on the subsequent prescribing of risperidone following generics; to utilise the findings to
provide future guidance to health authorities; and where possible, to investigate the utilisation of generic versus
originator risperidone and the prices for generic risperidone.
Methods: Principally, this was a segmented regression analysis of retrospective time-series data of the effect of the
various initiatives in Belgium, Ireland, Scotland and Sweden following the introduction of generic risperidone. The
study included patients prescribed at least one atypical antipsychotic drug up to 20 months before and up to 20
months after generic risperidone. In addition, retrospective observational studies were carried out in Austria and
Spain (Catalonia) from 2005 to 2011 as well as one English primary care organisation (Bury Primary Care Trust (PCT)).
Results: There was a consistent steady reduction in risperidone as a percentage of total selected atypical
antipsychotic utilisation following generics. A similar pattern was seen in Austria and Spain, with stable utilisation in
one English PCT. However, there was considerable variation in the utilisation of generic risperidone, ranging from
98% of total risperidone in Scotland to only 14% in Ireland. Similarly, the price of generic risperidone varied
considerably. In Scotland, generic risperidone was only 16% of pre-patent loss prices versus 72% in Ireland.
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Conclusion: Consistent findings of no increased prescribing of risperidone post generics with limited specific
demand-side measures suggests no ‘spillover’ effect from one class to another encouraging the preferential
prescribing of generic atypical antipsychotic drugs. This is exacerbated by the complexity of the disease area and
differences in the side-effects between treatments. There appeared to be no clinical issues with generic risperidone,
and prices inversely reflected measures to enhance their utilisation.
Keywords: Generics, Antipsychotics, Risperidone, Demand-side measures, Drug utilisation, Cross national studyBackground
Health authorities across Europe are increasingly struggling
to fund growing drug volumes and their associated costs
within available resources, as a result of ageing populations
and new premium-priced drugs [1,2]. This is already
resulting in some countries no longer funding new
premium-priced drugs, which is not in the best interest
of any stakeholder group [1-5]. Improved knowledge of
pharmacogenomics, leading to improved management
of patients with improved targeting of treatments, is
one way forward. However, there is a still an appreciable
number of challenges to address before such approaches
become routine [3].
In the meantime, there are considerable opportunities
for authorities across Europe to realise appreciable savings
from the increased use of low-cost generics [1]. The avail-
ability of generic risperidone provides a further opportunity
for authorities to achieve considerable savings. This is be-
cause worldwide sales of atypical antipsychotic drugs were
over $US 5 billion per year in the early 2000s, reaching
$14.6bn in the US alone in 2009 [6,7]. In addition, medicine
costs can be an appreciable component of the overall cost
of treating patients with schizophrenia, as pharmacological
treatments represent the backbone of managing these
patients [8-11].
We acknowledge that there is continuing debate about
the relative merits of atypical versus typical antipsychotics
in the management of patients with schizophrenia [12-16].
Recent studies have suggested that pharmacological
treatments should be tailored, in view of the consider-
able variation in their effectiveness between individual
patients [12,17-20]. In addition, there are also consid-
erable differences in side-effects between the different
atypical antipsychotic drugs, including weight gain,
hyperlipidaemia and type 2 diabetes [12,17,19]. The risk
of QT prolongation and subsequent arrhythmia-related
events, i.e. torsade de pointes (TdP) and sudden cardiac
death, has also become increasingly important [21,22].
Previously, atypical antipsychotic drugs were generally per-
ceived as having a more favourable safety profile in terms
of cardiac and extrapyramidal side-effects. However, this is
changing, with post-marketing studies and meta-analyses
challenging the definition of typical (first generation) or
atypical (second generation) antipsychotic drugs [18,23-27].Recent studies have also shown that the risk of mortality in
patients with schizophrenia is highest with quetiapine and
lowest with clozapine [28]. However, there have been con-
cerns regarding patient selection in this cohort study. Halo-
peridol and risperidone had slightly lower adjusted hazard
ratios than quetiapine [28].
However, other authors believe the modest health
gains achieved with atypical antipsychotic drugs reported
in the literature do not adequately reflect the improvement
in the quality of life perceived by patients, clinicians or
carers [29]. This has resulted in the increasing use of these
drugs in recent years, which is likely to continue despite
safety concerns [30-37].
As a result, the introduction of generic atypical anti-
psychotic drugs should be welcomed by European au-
thorities in order to save costs. However, it is recognised
by health authorities that schizophrenia and bipolar disor-
ders are complex diseases to treat compared with hyper-
cholesterolaemia, hypertension or acid-related stomach
disorders, for instance. In addition, atypical antipsychotic
drugs cannot be considered as a single class, because of
the heterogeneity of their pharmacological activities. This
is unlike the situation for proton pump inhibitors (PPIs),
renin-angiotensin inhibitor drugs or statins [1,38-45]. In
view of this, as mentioned, there is a greater need to tailor
treatments to individual patients. This complexity has re-
sulted in limited demand-side initiatives by national and
regional health authorities across Europe to preferentially
encourage the prescribing of oral risperidone versus pat-
ented atypical antipsychotic drugs once generic risperi-
done became available [46-48]. Limited measures included
physician prescribing quotas for low-cost medicines in
Belgium, advice to psychiatrists to consider preferentially
starting patients on generic atypical antipsychotic drugs
where pertinent in Scotland, and prescribing restric-
tions for long-acting risperidone injections in Austria
and Belgium [46-48].
Consequently, the principal objective of this study was
to compare and contrast the effect of the limited demand-
side measures instigated by Western European countries
and regions to enhance the prescribing of risperidone ver-
sus patented atypical antipsychotic drugs once oral generic
risperidone became available. A secondary objective was to
utilise the findings to provide guidance to health authorities
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enhance the prescribing of generic atypical antipsychotic
drugs if this is practical and feasible. This is because we
would expect to see limited change in the utilisation of
risperidone following generics with limited demand-side
measures and the recognised need to tailor pharmacother-
apy. This builds on previous findings across a range of
classes, including antidepressants, PPIs, renin-angiotensin
inhibitor drugs and statins [1,38-41,47,49,50]. We also
investigated the utilisation of generic versus originator
risperidone because a universally low utilisation of gen-
eric risperidone would represent concerns with generics
among either patients or physicians, or both. Finally, we
investigated prices for generic risperidone versus pre-
patent loss prices to provide guidance to countries that
still have high prices for generics.
Only Western European countries and regions were
chosen for analysis as generic atypical antipsychotic drugs
have been available for a longer time in Central and Eastern
European countries [6].
Methods
We principally undertook a segmented regression ana-
lysis of retrospective time-series analysis to assess the ef-
fect of various initiatives in Belgium, Ireland, Scotland
and Sweden following the introduction of generic risper-
idone [51]. The xtmixed command in Stata (version 12)
(StataCorp, College Station, Texas, USA) was used to fit
a linear random coefficient model with country-specific
intercepts. At the time of introduction of generic risperi-
done into each country, a random shift in intercepts and
slopes was allowed to estimate the effect of the introduc-
tion. Data on the number of monthly reimbursed pre-
scriptions within each country’s health service for all
patients prescribed at least one atypical antipsychotic
drug (N05AH03 to 06, N05AL05, N05AX08, N05AX011
to 13) [52] up to 20 months before and up to 20 months
after the availability of generic risperidone was included.
Clozapine was not included in the analysis as it is gener-
ally reserved for patients not responding to other atypical
antipsychotic drugs because of its side-effect profile
[46,53-55]. Ziprasidone (N05AE04) was also not included.
This was in view of its different classification and limited
utilisation in practice in a number of European countries,
including Sweden [56].
A retrospective observational study of the same popu-
lation dispensed at least one atypical antipsychotic drug
was also undertaken in Austria and one of the regions in
Spain (Catalonia) from January 2005 (Austria) or January
2006 (Spain) to the end of 2010 (Austria) and September
2011 (Spain). This was because generic risperidone was
already available in Austria and Spain in July 2004 and
by January 2006 respectively, but only became available
later in the four chosen European countries: Ireland inDecember 2007, Scotland in April 2008, and Belgium
and Sweden in January 2009. A retrospective observational
study was also undertaken in one English primary care
organisation, Bury Primary Care Trust (PCT), between
November 2009 and October 2011. The objective was
to assess the influence of a request to psychiatrists to
consider oral risperidone as first line treatment in new
or other suitable patients, where appropriate, now it
was available as a generic.
Finally, retrospective observational studies were under-
taken on the utilisation of long-acting risperidone injections
versus total risperidone (N05AX08) [52], which was
available throughout the study period, as well as pali-
peridone (N05AX13) before and after the availability of
generic oral risperidone.
The European countries chosen provide a range of
differences in geographical location, population size,
different approaches to the financing of health care,
and different approaches to the pricing of generics and
to enhancing the utilisation of generics versus originators
[39,40], which is in line with recommended guidance [57].
Only administrative databases were used in each coun-
try to assess the utilisation and expenditure patterns of
the atypical antipsychotic drugs. This is because the per-
spective of the study was that of health authorities, and
they typically have the greatest knowledge concerning
existing and planned initiatives and reforms in their
countries. The databases, which are regularly audited,
are included in Box 1. Box 1 also contains details of patients
included within the national health service of each country.
This typically includes 100% or close to 100% of the popu-
lation unless stated (Ireland), given the principles of equity
and solidarity within European healthcare systems. There
are also typically limited patient co-payments.
The utilisation of the different atypical antipsychotics
was calculated in terms of defined daily dose (DDD),
which is defined as ‘the average maintenance dose of a
drug when used in its major indication in adults’, as this
measure is recognised as the international standard to
assess utilisation patterns within and between countries
[58]. The only exception was Bury PCT, where utilisa-
tion was measured in terms of prescription items, which
is the typical metric used to assess utilisation patterns in
England [59]. 2011 DDDs were used in line with inter-
national guidance [58,60,61].
Separate retrospective observational studies were con-
ducted in Belgium, Scotland and Sweden, again using an
interrupted time-series methodology. The objective was
to assess whether the changes in risperidone utilisation
patterns after the introduction generic risperidone in
these three countries were significant [46,48,56].
Subsequently, risperidone utilisation in Belgium, Ireland,
Scotland and Sweden was converted into a percentage of
total selected atypical antipsychotic utilisation (DDD basis)
Box 1 – Administrative databases used in the study
[39-41,46-48,56,59,68,86,88]
• Austria: Internal data warehouse of the HVB (Hauptverband der
Österreichischen Sozialversicherungsträger) – BIG – coupled with
Cube HMSTAT, based on the ‘Maschinelle Heilmittelabrechnung’.
This provides reimbursement data on medicines dispensed in
ambulatory care in approximately 98% of the Austrian
population.
• Belgium: Pharmanet, a database of reimbursed medicines
dispensed in ambulatory care in Belgium. This database is
maintained by the National Institute for Health and Disability
Insurance and covers the whole Belgian population.
• England (Bury PCT): National Health Service Business Services
Division prescription pricing database (ePACT).
• Ireland: the National Shared Services Primary Care
Reimbursement Service of the Health Service Executive in
Ireland (HSE-PCRS) pharmacy claims database. This database
provides details on monthly dispensed medications for each
individual within the GMS population. The GMS population
covers approximately 30% of the population of Ireland with
higher morbidity than the general population, which is reflected
in their consumption of approximately 65% of total
pharmaceutical expenditure in Ireland.
• Scotland: NHS National Services Scotland Corporate
Warehouse, covering the entire population in Scotland.
• Spain (Catalonia): DMART (Catalan Health Service) database,
covering the public system in Catalonia.
• Sweden: National Swedish Pharmacy Register covering the
entire Swedish population.
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(time 0). The objective was to enable meaningful compari-
sons between the four countries, factoring in differences
in population sizes, time when generic risperidone became
available, and differences in their database characteristics
(Box 1). Utilisation patterns and calculations were verified
with the relevant co-authors to enhance the robustness of
the study findings.
The percentage of oral risperidone dispensed as ge-
nerics was also calculated in Belgium, Ireland, Scotland
and Sweden. We would expect to see considerable dif-
ferences in utilisation rates between countries in view
of the different policies in each country regarding en-
couraging the utilisation of generics versus originators
[39,40,62-65]. However as mentioned, a universally low
utilisation of generic risperidone would reflect general
stakeholder concerns with generic risperidone.
The percentage reduction in expenditure per DDD for
oral generic risperidone versus pre-patent loss originatorprices was also calculated in Belgium, Ireland, Scotland
and Sweden. We chose to compare relative reductions
rather than actual prices for generic risperidone as the
price components can vary in each country (for example,
there are variations in the extent of VAT and relative
wholesaler margins), and this approach also avoids currency
conversions, both of which can make cross-country price
comparisons difficult, especially during times of economic
difficulty. In addition, prices of initial or all generics in an
appreciable number of European countries are based on
pre-patent loss prices [39,40,62,64,65], and the time periods
for the availability of generic risperidone varied consider-
ably between the countries and regions studied. We also
did not factor inflation into the calculations because the
trend in most European countries is to reduce prices when
pharmaceutical expenditure exceeds target budgets [39,66]
and, as mentioned, prices of generics in a number of Euro-
pean countries are based on pre-patent loss prices. This is
in line with previous studies [39,40,64]. We would again ex-
pect to find considerable differences in the prices of generic
risperidone between countries, because of the different pri-
cing initiatives and differences in the attractiveness in the
generic market [1,38,39,62,64,67].
Finally, we calculated the influence of the availability of
generic risperidone on subsequent atypical antipsychotic
expenditure where possible.
No ethics approval was needed or obtained because only
aggregated drug utilisation data was used, without access
to specific patient data.
Results
There was a consistent steady reduction in the utilisation
of risperidone as a percentage of total selected atypical
utilisation in all the four countries over time following the
introduction of generic risperidone (Figure 1).
There were significant differences in the rate of utilisa-
tion of risperidone between the four countries before
generic risperidone was launched (Table 1, initial slope).
However, there was less variation in the utilisation of
risperidone between the four European countries after
generic drugs became available (Figure 1, Table 1). The
average decline in the percentage of risperidone versus
the other selected atypical antipsychotic drugs persisted
after generic risperidone was introduced but to a lesser ex-
tent, with an initial average drop of −0.0774 and a change
in slope from −0.144% to −0.00548% per month (Table 1).
However, this combined change in the slope after month
0 was not statistically significant.
There was variation between the four countries in the
rate of decline in the utilisation of risperidone after the
introduction of generic risperidone (month 0). Sweden
had the fastest decline, while Scotland, already having
the lowest levels of risperidone utilisation, had the slowest
decline (Table 2). However when combined, there was no
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Figure 1 Percentage utilisation of risperidone (defined daily dose (DDD) basis) versus selected atypical antipsychotic drugs among four
European countries. NB. *= No statistical difference in the rate of risperidone utilisation before and after the availability of generic risperidone in
separate country analyses.
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patterns following the introduction of generics (Table 1).
There was also no significant change in the utilisation of
risperidone after the introduction of generic risperidone
in separate single country studies conducted in Belgium,
Scotland and Sweden [46,48,56].
A similar pattern was also seen in Austria (Table 3)
and Spain (Catalonia) (Figure 2). In Spain, utilisation of
risperidone declined from 35% of selected atypical anti-
psychotic drugs in 2006 (DDD basis) to 28% by the third
quarter of 2011 (Figure 2).
In Bury PCT, the prescribing of risperidone averaged
between 16% and 21% of the selected atypical antipsy-
chotics dispensed between November 2009 and October
2011 (Figure 3). However, there was no recognised pat-
tern to the prescribing of risperidone, with its utilisation
varying randomly between the months. Again, utilisation
of selected atypical antipsychotic drugs was dominated
by olanzapine and quetiapine.
There was variation between the various European
countries and regions in the utilisation of long-acting
risperidone injections as a percentage of total risperidone.
This ranged from an average of 6% to 7% in Scotland to
18.5% to 20% in Sweden, and over 20% in Belgium, beforeTable 1 Characteristics of the utilisation of risperidone
after generic availability (month zero)
Consolidated atypical antipsychotics following generic risperidone
Coefficient value (95% CI) P-value
Initial intercept 22.70 (18.58 to 26.82) <0.001
Change in intercept at month 0 −0.0774 (−1.080 to 0.925) 0.880
Initial slope −0.144 (−0.158 to -0.130) <0.001
Change in slope after month 0 −0.00548 (−0.0545 to 0.0436) 0.827reducing in later months in Belgium following tightening
of the prescribing regulations versus oral risperidone [48].
There was generally low utilisation of paliperidone in
all the countries and regions studied (Table 4), despite
paliperiodone being available before oral generic risperi-
done in the four principal countries.
There was also considerable variation in the utilisation
of oral generic versus originator risperidone by the end
of the study period in each of the four principal countries
(Table 5). Similarly, there was considerable variation
between the four countries in the price reduction of
oral generic risperidone (expenditure/DDD) versus
pre-patent loss prices by the end of the study period.
In both Scotland and Sweden, the high utilisation of
generic risperidone at low prices (Table 5) resulted in
expenditure for atypical antipsychotic drugs increasing
at a lower rate than utilisation. Utilisation of the selected
atypical antipsychotic drugs in Scotland increased by
53% between 2005 and 2010, but expenditure increased
by only 42%. In Sweden, utilisation increased by 20% after
the introduction of oral generic risperidone until August
2011, with expenditure increasing by only 13%.Table 2 Slope of risperidone utilisation between the four
European countries after generic risperidone became
available (month 0)
Country Slopea
Belgium −0.165
Ireland −0.143
Scotland −0.075
Sweden −0.194
aA slope of −0.165 = a drop of 0.165%/month in the utilisation of risperidone
as a percenage of all selected atypical antipsychotics following the
introduction of generic risperidone.
Table 3 Utilisation of selected atypical antipsychotics in
Austria as a percentage of total atypical antipsychotic
use between 2005 and 2010 (defined daily dose basis)
Atypical
antipsychotic
2005 2006 2007 2008 2009 2010 % Change
Risperidone 31.6 29.9 28.6 26.9 25.5 23.8 -25
Amisulpride 8.4 7.1 6.7 6.3 5.9 5.5 -35
Aripiprazole 2.5 5.4 7.2 9.1 10.6 11.8 376
Olanzapine 36.6 33.3 31.3 29.6 28.0 26.1 -29
Quetiapine 18.6 22.5 24.8 27.0 29.6 32.7 75
Paliperidone 0.00 0.00 0.00 0.02 0.04 0.03 NA
Zotepine 2.2 1.8 1.4 0.9 0.4 0.1
NA, not applicable.
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As expected, there was no increase in the utilisation of
risperidone compared with the other atypical antipsychotic
drugs after the introduction of generic risperidone in either
Belgium, Ireland, Scotland or Sweden (Figure 1), or in Bury
PCT (Figure 3). In fact, if anything the reverse was seen,
with increased prescribing of patented atypical antipsy-
chotics in the four countries (Figure 1). A similar picture
was also seen in Austria and Spain (Table 3; Figure 2) with
generic extended release (ER) quetiapine not being available
in Spain until near the end of the study. However, there
were significant differences in the rate of decline in risperi-
done utilisation between the four countries before generic
risperidone was launched (Table 1). However, there was less
variation in the rate of decline after generic risperidone
became available (Figure 1; Table 1), with the combined
decline in risperidone utilisation falling to −0.00548% per0
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Figure 2 Utilisation of selected atypical antipsychotic drugs in Catalo
January 2006 to end of September 2011. NB. Generic immediate release
extended release (ER) quetiapine only became available in September 2011month from −0.144% per month (Table 1). The rate of de-
cline was greater in Sweden than Scotland (Table 2). How-
ever, there was overall a reasonable consistency between
the four countries, irrespective of their characteristics
[39,68], reflected by the lack of a statistically significant
change in slope after month 0 (Table 1). This was also no
statistically significant difference in the rate of risperidone
utilisation after generic risperidone became available in
the separate analyses conducted in Belgium, Scotland and
Sweden [46,48,56].
The consistent findings between the seven European
countries and regions, including Austria (Table 3), Spain
(Figure 2) and Bury PCT (Figure 3), regarding risperidone
utilisation following the introduction of generics would
suggest that following generic availability, there was no
increased prescribing of oral risperidone for new patients,
for whom risperidone could be one of the treatment
options. However, we cannot say this with certainty
without analysing patient-specific data. No increased
prescribing of risperidone following introduction of ge-
nerics (Figures 1, 2 and 3; Tables 1 and 3) may reflect the
advice from organisations such as the National Institute
for Health and Care Excellence in the UK and from various
published studies that treatment of patients with schizo-
phrenia should be individualised to maximise patient out-
comes [17-19,69,70]. The growing utilisation of the other
atypical antipsychotics, especially quetiapine and aripipra-
zole, in the various countries following the introduction of
generic risperidone (Figures 1 and 2; Table 3) may reflect
the marketing activities of the manufacturers of patented
atypical antipsychotic drugs including ER quetiapine in
Spain, influencing the choice of antipsychotic drugQu
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reflect the recognised weight neutrality with aripiprazole
versus olanzapine and risperidone, as well as the effective-
ness of aripiprazole and quetiapine ER in treating patients
with major depressive disorders who have had an incom-
plete response to antidepressants, and of quetiapine ER in
treating patients with bipolar depression [74-76], given the
limited utilisation of patented paliperidone in recent years
(Table 4). However, this remains to be elucidated in further
research. There was also no substantial increase in the util-
isation of long-acting risperidone in the four principal
countries following the introduction of oral generic risper-
idone. If anything, the reverse was seen in Belgium in re-
cent years, as reimbursement is denied if the medical
adviser appointed by the patient’s insurer is not satisfied
with the rationale provided by the physician [48].
The findings also potentially suggest there is no ‘spill-
over’ or cross-transfer of learning in practice from one
disease area to another to produce changes in physician
prescribing habits, that is, no crossover of learning to in-
crease the prescribing of generics when available as seen
with the PPIs, renin-angiotensin inhibitor drugs andTable 4 Maximum utilisation of paliperidone (oral and
injectable) as a percentage of total selected antipsychotic
utilisation in the various European countries and regions
Country Paliperidone (maximum), %
Austria 0.04
Belgium 4.8
Bury PCT 0.07
Ireland (GMS population) 1.01
Scotland 0.03
Spain (Catalonia) 3.99
Sweden 1.5
GMS - General Medical Services.statins [1,38-41,43-45,59,77]. We believe this is an
important finding from this research. However, this
finding is tempered by the recognised need to tailor
pharmacological treatment for patients with schizophrenia
or bipolar disease, especially with regard to issues such as
weight gain and effectiveness in different patient popula-
tions, as well as reluctance among physicians to switch
treatments when patients are stable on a particular
atypical antipsychotic drug.
We believe a second important finding is that in some
disease areas it is difficult for health authorities to en-
courage the preferential prescribing of multiple sourced
versus patented drugs, apart from introducing measures
such as prescribing restrictions for different formulations
of a molecule [48]. This illustrated by limited initiatives
in any of the seven countries and regions to enhance the
prescribing of oral risperidone following the introduction
of generics. This is unlike the situation for the PPIs, renin-
angiotensin inhibitor drugs and the statins [1,38,40,42,77].
We believe, based on our findings (especially those from
Bury PCT following its activities (Figure 3) when recently
it was very successful in significantly enhancing the
prescribing of generic losartan versus patented ARBs
(angiotensin receptor blocker) for treating hypertensionTable 5 Percentage utilisation of oral generic risperidone
versus total risperidone (DDD basis) and percentage
reduction in expenditure per defined daily dose for oral
generic risperidone versus pre-patent loss prices by the
end of the study period in each country
Country Utilisation of generic risperidone, % Price reduction, %
Belgium 52 59
Ireland 14 28
Scotland 98 84
Sweden 96 80
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ence of measures such as prescribing guidance or guide-
lines highlighting the preferential prescribing of generic
atypical antipsychotic drugs as first line treatments may
be limited. This is especially the case if there is a good
clinical rationale for prescribing a patented product in-
cluding concerns with weight gain. Additional measures
could include instigating reimbursement restrictions for
oral patented atypical antipsychotics, which is similar to
the situation for long-acting risperidone injections in
Austria and Belgium [47,48]. However, such measures
may again be difficult to implement, given the subjective
nature of choosing pharmacological treatment options
to maximise patient outcomes in these complex disease
areas, and may even be counterproductive.
The considerable variation between European countries
in the prescribing of oral generic risperidone versus origi-
nators (Table 5) reflects the different policies in these
countries to encourage use of generics. The high rates
seen in Scotland and Sweden suggest that there are no
problems with generic risperidone in clinical practice.
This is no doubt enhanced by the strict regulations for
granting marketing authorisation for generics in Europe,
with authorities removing generic products where con-
cerns exist [63,64,78]. Consequently, the differences are
down to different demand-side measures between the
four countries. The high utilisation of oral generic ris-
peridone in Scotland reflects generally high voluntary
INN (International Non-proprietary Name) prescribing
rates across classes. This starts with extensive physician
education in medical school to prescribe by INN, which
is followed up in ambulatory care through pharmacists
working for the Health Boards monitoring the prescrib-
ing of drugs [40,46,49]. The high rates in Sweden reflect
the instigation of compulsory generic substitution, in-
cluding risperidone, apart from in a limited number of
cases [39,40,56,77,79,80]. We believe the high voluntary
INN prescribing rates in the UK provides guidance to
other countries. This is because such activities reduce
patient confusion once multiple sources become available,
especially if patients are dispensed different branded
generics with different names on each occasion, without
adequate explanation. This can happen in Sweden with
compulsory generic substitution, apart from a limited
number of situations authorised by the Medicine Product
Agency [81], and more recently with monthly auctions as
the cheapest branded generic secures an appreciable pro-
portion of prescriptions for the molecule the following
month [1,38]. The dispensing of different branded generics
on each occasion can possibly cause confusion and concern
if patients do not receive adequate information about their
medicines [82]. This can potentially result in either dupli-
cation of medicines, or alternatively, in patients not taking
their prescribed treatments as directed, which could beproblematic [82,83]. INN prescribing, apart from a limited
number of well-known situations, is one way to address
this [49,80,84,85].
There were also appreciable differences between coun-
tries concerning the price of generic risperidone (Table 4).
This reflects the different policies between the four coun-
tries with regard to enhancing the utilisation of generics,
as well as their different pricing policies. The considerable
price reduction for generic risperidone in Scotland, which
is similar to those for other generics, follows recent re-
forms in the UK to enhance transparency in the cost of
producing generics, as well as discounts offered by manu-
facturers to wholesalers and pharmacists to preferentially
dispense their generic [41,49]. The price reduction in
Sweden, which is also similar to those for other generics,
is a result of the introduction of compulsory generic
substitution with the lowest priced molecule [1,38,80].
Generic prices are likely to fall further in Sweden with
the recent introduction of monthly auctions, with the
manufacturer who wins the auction being guaranteed a
considerable proportion of dispensed generics the fol-
lowing month [1,38]. The more modest price reduction
for generic risperidone in Belgium reflects the current
situation, where generic companies only have to lower
their prices to the reference price level to be reim-
bursed. This was only 16% versus pre-patent loss prices
until 2002, 20% until 2003, 26% until 2005, and is cur-
rently 31% [48,68,85]. The high prices for generics in
Ireland reflect the limited measures to date to reduce
these, although this is now changing [39,86]. These find-
ings are consistent with other research showing that the
lowest prices for generics in Europe are seen in countries
with the greatest market share [62,63,67]. Consequently,
measures to increase the attractiveness of the generic
market, as well as enhance the transparency in their
pricing, as seen in Sweden and the UK, provide guid-
ance to countries seeking ways to achieve further sav-
ings from the use of generics. This is especially the
case where it is difficult to encourage the preferential
prescribing of generics versus patented products, for
example, atypical antipsychotic drugs.
We are aware there are a number of limitations with this
study. This includes no access to patient data to assess
whether there has been an increase in the prescribing of
risperidone as first line treatment since the introduction of
generics. In addition, there is no knowledge of the
prescribed indications, especially with risperidone being the
only atypical antipsychotic drug currently licensed for
asymptomatic treatment in patients with dementia.
However, the consistent continued decline in the utilisa-
tion of risperidone following the introduction of generics,
coupled with increased utilisation of patented atypical
antipsychotic drugs (Figures 1 and 2; Table 3), suggests
there has been no increase in the prescribing of
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by increased awareness of the lack of effect on weight
with aripiprazole, and the effectiveness of aripiprazole
and quetiapine ER in major depressive disorders. We
have also not assessed whether there are any differences in
outcomes between oral generic and originator risperidone.
Previous research findings and the continued high utilisa-
tion of generic risperidone in Scotland and Sweden
(Table 5) suggest there are no problems with generic atyp-
ical antipsychotic drugs in clinical practice [6,46,49,50,87].
However, again, we cannot say this with certainty without
specific patient research. Finally, we are unable to deter-
mine or comment on the extent of any polypharmacy with
atypical antipsychotic drugs.
Conclusions
Generics provide a considerable opportunity for author-
ities to fund increased drug volumes and new premium-
priced drugs within available resources. However, there
are disorders such as schizophrenia for which it is difficult
to encourage the preferential prescribing of multiple
sourced drugs as first line treatments. This is due to the
recognised need to tailor pharmacological treatments to
the individual patient in order to maximise outcomes.
This belief has resulted in limited demand-side measures
by the seven European countries and regions to encourage
the preferential prescribing of generic versus patented
atypical antipsychotic drugs, compared with the multiple
measures generally instigated for the PPIs and statins
following introduction of generics. We have also shown
that authorities across Europe cannot rely on the transfer
of learning concerning the prescribing of generics as first
line treatment from one class to another in order to affect
changes in the prescribing habits of atypical antipsychotic
drugs. This is no doubt enhanced in this case by the need
to tailor treatments and the heterogeneity of the products
in the class. However, we believe that any demand-side ini-
tiatives, apart from encouraging one dosage form over an-
other, would have only a limited effect, owing to the
complexity of treating patients with schizophrenia or bipo-
lar disease, and the recognised differences in side-effect
profiles between the various pharmacological approaches.
Consequently, we do not believe the authorities in any of
the seven countries or regions studied are planning specific
measures in the future. This decision is no doubt helped by
more oral atypical antipsychotic drugs now being available
as multiple sourced products, helping to lower overall drug
acquisition costs.
Finally, we believe countries can learn from each other
regarding potential additional ways to further enhance the
prescribing of generic versus originator atypical anti-
psychotic drugs, and to obtain lower prices where pertinent.
This includes measures such as increasing INN prescrib-
ing and greater transparency in the pricing of generics.Competing interests
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